18 results about "Autophagosome" patented technology

Application of a high-purity inonotus obliquus polysaccharide component belongs to the technical field of biological medicine, and the high-purity inonotus obliquus polysaccharide component plays a role in preventing and treating by inhibiting autophagy of lung tissue cells and depending on an lncRNA Rmst pathway, and can reduce the number of autophagosomes in lung tissues and the level of conversion from LC3-I to LC3-II; according to the method, the sugar content of IOP can be remarkably increased compared with crude polysaccharide, the protein content is remarkably reduced, four active components with specific molecular weights are obtained through separation, the molecular weight ranges are definite (IOP-g1gt, IOP-g2gt, IOP-g3gt and IOP-g4), and the requirements of medicine research and development for controllable purity and definite components are met.

This application relates to the technical field of biological products, and provides an application, extraction method and composition of TGL-ELNs in the treatment of glioma. The TGL-ELNs are applied in any one or more of the following aspects: a) Preparation of products for promoting apoptosis of glioma cells; b) Preparation of products for inhibiting proliferation of glioma cells; c) Preparation of products for inhibiting autophagy of glioma cells; d) Preparation of products for treating glioma. Verified through cell and animal experiments, the TGL-ELNs in this application can effectively induce apoptosis of glioma cells and inhibit autophagy of glioma cells to induce glioma cell death, and act on glioma cells through the AKT / mTOR signaling pathway and by inhibiting the production of autophagosomes in glioma cells.

The application discloses oleanane triterpene saponin compounds with improved mitochondrial energy anti-aging, a preparation method and application thereof, and belongs to the technical field of medicines and cosmetics. Through systematic chemical component research on Zhejiang Hongshan tea flowers, two new oleanane triterpene saponin compounds CK and CL are separated, and the chemical structures are determined by using high-resolution mass spectrometry and nuclear magnetic technology. In-vitro anti-photoaging activity research shows that the new compounds CK and CL provided in the application have good protection effects on ultraviolet-induced fibroblast photoaging, can significantly improve the content of type I collagen, reduce the expression of matrix metalloproteinases mmp1 and mmp3 , increase the generation of mitochondrial autophagosomes and lysosomes, promote mitochondrial autophagy, relieve mitochondrial damage and improve cell senescence. The preparation method provided in the application is simple, and the activity is significant, so that the application is expected to be developed into a new anti-skin aging medicine or cosmetic.

The invention provides a fluorescent compound and application thereof in preparation of a specific imaging biological sample autophagy process probe or an autophagy regulator screening preparation, and belongs to the technical field of biological medicine. The fluorescent compound provided by the invention comprises a fluorophore, a linking group and an autophagy targeting group which are covalently bonded in sequence. The fluorescent compound provided by the invention is a small-molecule chemical probe, and is combined with an autophagy marker protein, namely a microtubule-associated protein light chain 3 (LC3 protein) in an affinity manner to realize high-specificity detection of an autophagy process; a dynamic signal dependent on the autophagy process is presented, fluorescence is turned on after combination with LC3 protein, and fluorescence changes color after fusion of an autophagosome and a lysosome, so that high-specificity, high-contrast and high-sensitivity living cell imaging detection of the autophagy process can be realized.

The invention relates to the technical field of medicinal chemistry, in particular to application of hovenia acerba total triterpenes to preparation of a medicine with a non-small cell lung cancer resisting effect. Researches show that the hovenia acerba total triterpenes have the effects of resisting NSCLC and enhancing sensitivity; the hovenia acerba total triterpenes can inhibit A549 cell proliferation, migration and apoptosis in a dose-dependent manner, and can stimulate the formation of autophagosome and induce an autophagy process, which indicates that the hovenia acerba total triterpenes have the effect of KNSCLC. The hovenia acerba total triterpenes can inhibit the activity of ARE-Leu luciferase and increase the cytotoxicity of the hovenia acerba total triterpenes combined with cisplatin, and the hovenia acerba total triterpenes combined with cisplatin can significantly reduce the protein expression of the Nrf2 pathway, which shows that the hovenia acerba total triterpenes have the effect of enhancing the sensitivity of NSCLC drug-resistant cells. Therefore, the hovenia acerba total triterpenes used as the active ingredient for preparing the medicine with the anti-NSCLC effect have important application value.

The invention relates to the technical field of biological medicine, in particular to an autophagosome for promoting hair growth and an extraction method and application thereof. Comprising the following steps: inoculating human umbilical vein endothelial cells or human placenta mesenchymal cells into a DMEM (Dulbecco Modified Eagle Medium) complete medium, and culturing until the cell fusion degree reaches 80-90%; replacing the DMEM complete culture medium with a serum-free DMEM culture medium, collecting supernate after culture is completed, and centrifuging the supernate to obtain a crude extract containing the autophagosome; and resuspending the crude extract by using PBS, adding an LC3 antibody, and finely extracting by using a paramagnetic particle method to obtain the autophagosome. The method has the advantages of simple operation process, no need of other inducers in the process of inducing the formation of the autophagosome, no too high requirements on laboratories, and high yield of the autophagosome, and provides an efficient, convenient, economical and practical treatment means for alopecia patients.

The invention provides a ricin antidote and application thereof, and relates to the technical field of biomedicine. The ricin antidote provided by the invention comprises a first ligand, a connecting arm and a second ligand, the first ligand and the second ligand are connected through a connecting arm; the first ligand is a nucleic acid aptamer of ricin, and the nucleic acid sequence is as shown in SEQ ID NO. 1; and the second ligand is selected from an E3 ligase ligand, a hydrophobic molecule or an LC3 ligand. The ricin antidote is designed on the basis of a proteolysis targeting chimera technology, a hydrophobic labeling targeting proteolysis technology and an autophagosome binding compound technology, and a nucleic acid aptamer of ricin can be specifically bound with ricin, so that the combination of ricin and ribosome is inhibited, and irreversible damage is reduced; the degradation of the ricin is induced through an E3 ligase ligand, a hydrophobic molecule or an LC3 ligand, so that a reference is provided for related researches on the degradation of the ricin in the future.

The invention relates to the technical field of medicines, in particular to application of allicin in preparation of antitumor drugs, and the tumor is colorectal cancer. The allicin activates autophagy by regulating the lncRNAUCA1 to inhibit colorectal cancer cells, cell proliferation of an allicin treatment group is remarkably inhibited, apoptosis is remarkably increased, meanwhile, the number of invasive cells and the wound healing rate are remarkably inhibited, the gene level of the lncRNAUCA1 is remarkably reduced, the number of autophagosomes is remarkably increased, and dose dependence is achieved.

A method for measuring autophagosome flux is provided. The autophagosome pool size in a single cell is quantified, where the pool size is the total number of autophagosomes in the cell. Fusion between the autophagosomes and lysosomes in the cell is then inhibited. The autophagosome pool size is quantified over one or more time points after fusion has been inhibited, and the autophagosome flux is calculated as the initial rate of change of the autophagosome pool size at the time point after fusion has been inhibited. The method can be used to determine basal autophagosome flux, whether a cell is diseased or dysfunctional, or to diagnose a subject with a disease, disorder or dysfunction. The transition time, the time required to clear an autophagosome pool, can also be derived from the autophagosome flux. A molecule can also be characterized according to its ability to modulate autophagosome flux in a cell.

The invention discloses a traditional Chinese medicine composition for treating or adjunctively treating chronic obstructive pulmonary diseases. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20-40 parts of astragalus membranaceus, 10-30 parts of fried codonopsis pilosula, 10-14 parts of fried bighead atractylodes rhizome, 13-18 parts of poria cocos, 10-14 parts of bamboo juice pinellia ternate, 7-11 parts of pericarpium citri reticulatae, 10-14 parts of radix peucedani, 10-14 parts of cortex moutan and 1-5 parts of honey-fried licorice root. Tests prove that the traditional Chinese medicine composition and the traditional Chinese medicine extract can improve lung functions, relieve lung inflammatory cell infiltration, inhibit generation of inflammatory factors and reduce airway inflammatory response; in addition, diaphragm pathological injury can be relieved, formation of autophagosome is reduced, expression of ubiquitin-proteasome pathway symbolic protein is inhibited, and diaphragm atrophy is delayed, so that the chronic obstructive pulmonary disease is comprehensively treated, a new thought is provided for treatment of respiratory system diseases such as the chronic obstructive pulmonary disease, and the pharmaceutical composition is worthy of popularization and application. The traditional Chinese medicine composition has important clinical application and market promotion values.

The application discloses a kind of cotton callus autophagy activity visual detection technology, first using pretreatment buffer to incubate callus, then using PBS buffer transition, using MDC dyeing liquid is dyed, prepare cell suspension, observation.The application increases the level of cell autophagy by pretreatment induction, significantly improves the fluorescence staining intensity, improves the contrast of specific dyed autophagosome and background, so that autophagy in cell is more easily observed;Meanwhile, the pretreatment buffer has the effect of maintaining osmotic pressure, keeping liquid environment pH stable and providing basic nutrition, which can significantly improve the stability of staining.The application uses PBS buffer to wash, which can avoid over-staining and reduce the degree of background clutter.The staining step of the application is more simple, with clear staining levels and clear cell contrast, so that the autophagy phenomenon in plant somatic embryogenesis process is efficiently visualized.

This invention relates to the field of biomedical technology, disclosing extracellular vesicles derived from Poria cocos and their application in the development and preparation of drugs for the prevention or treatment of metabolic-associated steatohepatitis (MAS). The drugs improve liver tissue morphology and pathological lesions, regulate serum and liver lipid levels and inflammatory factor levels, and regulate mitochondrial structure and function, including alleviating mitochondrial ultrastructural damage, increasing the number of autophagosomes, improving oxidative stress and energy metabolism, promoting the expression of mitochondrial autophagy-related proteins, and reducing the production and efflux of Ox-mtDNA, thereby inhibiting the expression of NLRP3 inflammasome-related proteins. These drugs can improve MAS and provide a new direction for the development and research of drugs for the prevention and treatment of MAS.

This invention belongs to the field of biomedical technology, specifically relating to the application of piRNA-45962 inhibitors in the preparation of drugs for preventing and treating myocardial ischemia-reperfusion injury. This invention discovers that piRNA-45962, with the nucleotide sequence shown in SEQ ID No. 1, is specifically highly expressed during myocardial ischemia-reperfusion. Furthermore, specific inhibitors of piRNA-45962 can improve the blockage of autophagic flux during myocardial ischemia-reperfusion through the HNRNPH1 / GATA5 signaling pathway, enhance the clearance of autophagosomes by cardiomyocytes, reduce cardiomyocyte apoptosis, and exert a preventive and therapeutic effect against myocardial ischemia / reperfusion injury. This invention provides a new solution for the prevention and treatment of myocardial ischemia-reperfusion injury and offers new ideas for the development of drugs for the prevention and treatment of myocardial ischemia-reperfusion injury, possessing promising application prospects and clinical value.

Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of the pathogenic protein is provided, which comprises a nanocarrier and a protein-targeting binding peptide grafted on the nanocarrier. The nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; on the other hand, the use of the nanocomposite in the preparation of drugs including an anti-tumor nanodrug and a Huntington's disease inhibiting drug is provided. The nanocomposite can simulate a key receptor protein in a selective autophagy pathway, so that the pathogenic protein to be degraded can be brought into an autophagosome to be degraded by means of an autophagy pathway, thereby effectively solving the problem that PROTACs cannot degrade large-molecular-weight protein aggregates and LYTACs cannot degrade cytoplasmic proteins.

The present invention discloses an autophagosome for promoting the healing of diabetic wounds, its preparation method and application, belonging to the technical field of biomedicine. The present invention provides a preparation method of the autophagosome, which extracts the autophagosome from starved vascular endothelial cells. The generation of the autophagosome does not require additional reagents for induction, and the extraction conditions are simple. It does not require an ultra-high speed centrifuge and can be experimented in an ordinary laboratory. Moreover, the yield is higher than that of exosomes, providing a non-toxic and side-effect-free, easy-to-generate and low-cost treatment method for patients with chronic refractory wounds. The autophagosome of the present invention can promote the healing of diabetic wounds and relieve the physiological and psychological burdens caused by diabetic wounds to patients.

The invention relates to a herba epimedii extract for activating cell autophagy and a preparation method and application thereof.The herba epimedii extract is prepared from specific zymophyte and compound enzyme, the content of icariside I in the herba epimedii extract is increased, and the herba epimedii extract can activate cell autophagy by up-regulating expression of lysosome mannosidase (LManV). The composition has the advantages that the autophagy flow of cells is obviously enhanced, the fusion of autophagosome and lysosome is promoted, the p62 / Ref( 2) P accumulation caused by the decline of the autophagy function is efficiently reversed, the steady state of the environment in the cells is maintained, the aging speed of the cells is delayed, the support is provided for the aging resistance of the organism from the cellular level, the improvement of the aging-related physical state and the maintenance of the vitality of the organism are helped, and the composition is safe and non-toxic to the human body.

The present application relates to a kind of activation of cell autophagy Epimedium extract and its preparation method and application, the present application is prepared using specific fermentation bacteria and composite enzyme Epimedium extract, improve the content of Epimedium in Epimedium extract Epimedium secondary glycoside I, the Epimedium extract can be up-regulated lysosome mannose glycosidase (LManV) expression, significantly enhance cell autophagy flow, promote autophagosome and lysosome fusion, efficiently reverse the p62 / Ref (2) P accumulation caused by autophagy function decline, maintain intracellular environment steady, delay cell aging speed, provide support for organism anti-aging from cell level, help to improve the physical condition related to aging, maintain organism activity, and safe and nontoxic to human body.

The present invention provides a hydrazine compound, its preparation method, and its use as a buffered fluorescent probe (BFP) in lysosomes and autophagosomes. The hydrazine compound Z11 of the present invention can be used to prepare a buffered fluorescent probe (BFP) for ultra-long-term stable imaging within the physiological pH range. The buffered fluorescent probe is bleached within the lysosome and / or autophagosome, and the intact external probe is exchanged into the lysosome and / or autophagosome to continue fluorescence imaging. This strategy not only provides fluorescence imaging of the newly generated target (lysosome and / or autophagosome), but also ensures that the photobleached fluorescent probe within the target (lysosome and / or autophagosome) is effectively replaced by the new, intact fluorescent probe surrounding the target (lysosome and / or autophagosome), thus ensuring the stability of fluorescence imaging.